Promising Phase 2 Results for aTyr Pharma’s Efzofitimod in SSc-ILD Boost Investor Confidence

Analyst Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on aTyr Pharma (ATYR – Research Report) and keeping the price target at $35.00.

Joseph Pantginis’s rating is based on promising interim results from aTyr Pharma’s Phase 2 study of their lead therapeutic candidate, efzofitimod, in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD). The study, which is a randomized, double-blind, placebo-controlled trial, showed stable or improved skin scores in all patients, with significant improvements in some efzofitimod-treated patients. Additionally, preliminary signals of improvement were observed in key inflammatory and disease biomarkers, indicating potential efficacy of the treatment.
Furthermore, efzofitimod was generally safe and well-tolerated across all doses, with no treatment-related adverse events reported. This data update is seen as a significant step forward for aTyr Pharma, as they continue to expand the reach of efzofitimod. The ongoing Phase 3 study for pulmonary sarcoidosis further supports the potential of efzofitimod, with results expected in the third quarter of 2025, which could enhance aTyr Pharma’s visibility among investors.

In another report released today, JonesTrading also maintained a Buy rating on the stock with a $22.00 price target.

Based on the recent corporate insider activity of 6 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ATYR in relation to earlier this year.